Total Neoadjuvant Therapy for Operable Pancreatic Cancer

Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer

(2020) David Wittmann et al.   Frontiers in Oncology

Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer

(2019) Mark J. Truty et al.   ANNALS OF SURGERY

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

(2019) Salah-Eddin Al-Batran et al.   LANCET

Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort

(2019) Hampig Kourie et al.   Clinics and Research in Hepatology and Gastroenterology

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer

(2019) Janet E. Murphy et al.   JAMA Oncology

Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX

(2019) Timothy J. Vreeland et al.   PANCREAS

Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial

(2019) Alice C. Wei et al.   ANNALS OF SURGICAL ONCOLOGY

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma

(2018) Janet E. Murphy et al.   JAMA Oncology

A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma

(2018) Susan Tsai et al.   ANNALS OF SURGERY

Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer

(2018) Susan Tsai et al.   ANNALS OF SURGERY

How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort

(2018) Daniel Pietrasz et al.   ANNALS OF SURGICAL ONCOLOGY

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

(2018) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

(2017) John P Neoptolemos et al.   LANCET

Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer

(2017) Andrea Cercek et al.   Journal of the National Comprehensive Cancer Network

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience

(2016) Jordan M. Cloyd et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy

(2016) Kathleen K. Christians et al.   SURGERY

Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer

(2016) George Younan et al.   SURGICAL CLINICS OF NORTH AMERICA

Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer

(2016) Matthew H. G. Katz et al.   JAMA Surgery

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial

(2015) C. Fernandez-Martos et al.   ANNALS OF ONCOLOGY

Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy

(2015) Douglas B. Evans et al.   ANNALS OF SURGICAL ONCOLOGY

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

(2015) Alix Portal et al.   BRITISH JOURNAL OF CANCER

Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma

(2015) Amudhan Pugalenthi et al.   JOURNAL OF SURGICAL ONCOLOGY

The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma

(2014) Wenchuan Wu et al.   ANNALS OF SURGICAL ONCOLOGY

Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?

(2014) K. K. Christians et al.   ONCOLOGIST

Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic Cancer

(2013) Ryan P. Merkow et al.   ANNALS OF SURGERY

Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer

(2013) Helmut Oettle et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Current Staging Systems for Pancreatic Cancer

(2012) Betsy L. Appel et al.   CANCER JOURNAL

EMT and Dissemination Precede Pancreatic Tumor Formation

(2012) Andrew D. Rhim et al.   CELL

Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma

(2012) Kathleen K. Christians et al.   JOURNAL OF SURGICAL ONCOLOGY

Management of Patients with Pancreatic Adenocarcinoma: National Trends in Patient Selection, Operative Management, and Use of Adjuvant Therapy

(2011) Skye C. Mayo et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

(2010) Stephen B. Edge et al.   ANNALS OF SURGICAL ONCOLOGY